{"id":33500,"date":"2020-08-13T14:31:57","date_gmt":"2020-08-13T13:31:57","guid":{"rendered":"https:\/\/www.biotechpharmasummit.com\/?page_id=33500"},"modified":"2021-03-18T11:24:11","modified_gmt":"2021-03-18T11:24:11","slug":"cate-lockhart","status":"publish","type":"page","link":"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/cate-lockhart\/","title":{"rendered":"Cate Lockhart"},"content":{"rendered":"<div class=\"vgblk-rw-wrapper limit-wrapper\">\n<h2>Cate Lockhart, MS, PharmD, PhD<\/h2>\n<h4>Program Director at Biologics and Biosimilars Collective Intelligence Consortium (BBCIC.org)<\/h4>\n\t<p>Cate Lockhart, MS, PharmD, PhD is the Program Director for the Biologics and Biosimilars Collective Intelligence Consortium (BBCIC.org) where she is responsible for both the business and research programs of this large, multi-stakeholder research collaboration.<\/p>\n<p>Previously she was the HEOR expert at Omeros Corp in addition to part-time work with BBCIC as Research Team Coordinator. She also conducted several projects in health economics and outcomes research as an independent consultant. Prior to that Dr. Lockhart was Associate Clinical Director at Strategic Pharmacy Innovations.<\/p>\n<p>She has done extensive research, medical writing and consulting in multiple disease states and therapeutic areas, producing clinical and economic reviews, pharmacoeconomic models and AMCP dossiers to support formulary decisions and value assessments of pharmaceutical products across a variety of therapeutic areas. Cate has a unique breadth of formal training and practical experience and knowledge in basic science, managed care pharmacy, clinical analyses and quantitative sciences including outcomes research, health economics and epidemiology.<\/p>\n<p>Cate has three undergraduate degrees: B.S. in Electrical Engineering, B.S. in Visual Communications, and B.F.A. in Theatre Arts. She completed three advanced degrees from the University of Washington in Seattle: the PharmD, the M.S. in Health Economics and Outcomes Research and the Ph.D. in Pharmaceutical Sciences. She has a U.S. Patent, \u201cCalibration Method and System for PET Scanners.\u201d<\/p>\n\t\t\t\t\t\t\t<img decoding=\"async\" loading=\"lazy\" src=\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Lockhart_Cate_Biologics_Biosimilars_Collective_Intelligence_Consortium_BBCIC_BioTech_Pharma_Summit_2.jpg\" alt=\"Lockhart_Cate_Biologics_Biosimilars_Collective_Intelligence_Consortium_BBCIC_BioTech_Pharma_Summit_2\" itemprop=\"image\" height=\"1224\" width=\"820\" title=\"Lockhart_Cate_Biologics_Biosimilars_Collective_Intelligence_Consortium_BBCIC_BioTech_Pharma_Summit_2\" onerror=\"this.style.display='none'\" sizes=\"(max-width: 768px) 100vw, 100vw\" srcset=\"data:image\/svg+xml;utf8,<svg%20xmlns=&quot;http:\/\/www.w3.org\/2000\/svg&quot;%20viewBox=&quot;0%200%20820%201224&quot;%20height=&quot;1224px&quot;%20width=&quot;820px&quot;\/>&#8221; data-srcset=&#8221;https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Lockhart_Cate_Biologics_Biosimilars_Collective_Intelligence_Consortium_BBCIC_BioTech_Pharma_Summit_2.jpg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Lockhart_Cate_Biologics_Biosimilars_Collective_Intelligence_Consortium_BBCIC_BioTech_Pharma_Summit_2-201&#215;300.jpg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Lockhart_Cate_Biologics_Biosimilars_Collective_Intelligence_Consortium_BBCIC_BioTech_Pharma_Summit_2-686&#215;1024.jpg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Lockhart_Cate_Biologics_Biosimilars_Collective_Intelligence_Consortium_BBCIC_BioTech_Pharma_Summit_2-768&#215;1146.jpg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Lockhart_Cate_Biologics_Biosimilars_Collective_Intelligence_Consortium_BBCIC_BioTech_Pharma_Summit_2-630&#215;940.jpg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Lockhart_Cate_Biologics_Biosimilars_Collective_Intelligence_Consortium_BBCIC_BioTech_Pharma_Summit_2-420&#215;627.jpg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Lockhart_Cate_Biologics_Biosimilars_Collective_Intelligence_Consortium_BBCIC_BioTech_Pharma_Summit_2-315&#215;470.jpg 315w&#8221;>\t\t\t\t\t\t\t\n<h3>\n\tTitle: The state of US biosimilar utilization and post-marketing surveillance initiatives to support treatment and coverage decisions\n\t<\/h3>\n<ul>\n<li>Describe the background of generic drug uptake in the United States and how it relates to the current biosimilar market landscape<\/li>\n<li>Discuss some of the barriers to market access and utilization of biosimilars in the US: Regulatory questions; Commercial tactics; Stakeholder uncertainty<\/li>\n<li>Explain the limitations of clinical trial data in supporting clinical and formulary decisions<\/li>\n<li>Describe one approach to addressing the lack of real-world data and how it could be used for treatment and coverage decision<\/li>\n<\/ul>\n\t<a href=\"\" target=\"_blank\" role=\"button\" rel=\"noopener noreferrer\">\n\t\t\t\t\tPresentation not available\n\t<\/a>\n<h4>\n\t\t\t<a href=\"#\" title=\"On the Web\" target=\"_self\" rel=\"noopener noreferrer\">\n\tOn the Web\n\t\t\t<\/a>\n\t<\/h4>\n\t<p><a href=\"https:\/\/www.bbcic.org\/\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/www.bbcic.org\/<\/a><\/p>\n<h4>\n\t\t\t<a href=\"#\" title=\"On LinkedIn\" target=\"_self\" rel=\"noopener noreferrer\">\n\tOn LinkedIn\n\t\t\t<\/a>\n\t<\/h4>\n\t<p><a href=\"https:\/\/www.linkedin.com\/in\/catelockhart\" target=\"_blank\" rel=\"noopener noreferrer\">Visit Profile<\/a><\/p>\n<\/div><!-- .vgblk-rw-wrapper -->","protected":false},"excerpt":{"rendered":"<p>Cate Lockhart, MS, PharmD, PhD Program Director at Biologics and Biosimilars Collective Intelligence Consortium (BBCIC.org) Cate Lockhart, MS, PharmD, PhD is the Program Director for the Biologics and Biosimilars Collective Intelligence Consortium (BBCIC.org) where she is responsible for both the business and research programs of this large, multi-stakeholder research collaboration. Previously she was the HEOR&#8230;<\/p>\n","protected":false},"author":1,"featured_media":33501,"parent":33455,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"inline_featured_image":false,"footnotes":""},"class_list":["post-33500","page","type-page","status-publish","has-post-thumbnail","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.2 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Cate Lockhart &#8226; BioTech Pharma Summit<\/title>\n<meta name=\"description\" content=\"Joa\u0303o Gonc\u0327alves is Head of the Biopharmaceutical Biotechnology Unit at the Institute of Innovative Medicines and Instituto de Medicina Molecular\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/cate-lockhart\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cate Lockhart &#8226; BioTech Pharma Summit\" \/>\n<meta property=\"og:description\" content=\"Joa\u0303o Gonc\u0327alves is Head of the Biopharmaceutical Biotechnology Unit at the Institute of Innovative Medicines and Instituto de Medicina Molecular\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/cate-lockhart\/\" \/>\n<meta property=\"og:site_name\" content=\"BioTech Pharma Summit\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/biotechpharmasummit\/\" \/>\n<meta property=\"article:modified_time\" content=\"2021-03-18T11:24:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Lockhart_Cate_Biologics_Biosimilars_Collective_Intelligence_Consortium_BBCIC_BioTech_Pharma_Summit.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"900\" \/>\n\t<meta property=\"og:image:height\" content=\"900\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@biotechsummit\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/cate-lockhart\/\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/cate-lockhart\/\",\"name\":\"Cate Lockhart &#8226; BioTech Pharma Summit\",\"isPartOf\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/cate-lockhart\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/cate-lockhart\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Lockhart_Cate_Biologics_Biosimilars_Collective_Intelligence_Consortium_BBCIC_BioTech_Pharma_Summit.jpg\",\"datePublished\":\"2020-08-13T13:31:57+00:00\",\"dateModified\":\"2021-03-18T11:24:11+00:00\",\"description\":\"Joa\u0303o Gonc\u0327alves is Head of the Biopharmaceutical Biotechnology Unit at the Institute of Innovative Medicines and Instituto de Medicina Molecular\",\"breadcrumb\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/cate-lockhart\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/cate-lockhart\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/cate-lockhart\/#primaryimage\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Lockhart_Cate_Biologics_Biosimilars_Collective_Intelligence_Consortium_BBCIC_BioTech_Pharma_Summit.jpg\",\"contentUrl\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Lockhart_Cate_Biologics_Biosimilars_Collective_Intelligence_Consortium_BBCIC_BioTech_Pharma_Summit.jpg\",\"width\":900,\"height\":900},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/cate-lockhart\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.biotechpharmasummit.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Biosimilars &#038; Biologics 2019 Speakers\",\"item\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Cate Lockhart\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#website\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/\",\"name\":\"BioTech Pharma Summit\",\"description\":\"The Tomorrow&#039;s healthcare congress\",\"publisher\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.biotechpharmasummit.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#organization\",\"name\":\"EPM Group\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png\",\"contentUrl\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png\",\"width\":2000,\"height\":2000,\"caption\":\"EPM Group\"},\"image\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/biotechpharmasummit\/\",\"https:\/\/x.com\/biotechsummit\",\"https:\/\/www.instagram.com\/biotechpharmasummit\/\",\"https:\/\/www.linkedin.com\/company\/biotech-pharma-summit\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cate Lockhart &#8226; BioTech Pharma Summit","description":"Joa\u0303o Gonc\u0327alves is Head of the Biopharmaceutical Biotechnology Unit at the Institute of Innovative Medicines and Instituto de Medicina Molecular","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/cate-lockhart\/","og_locale":"en_US","og_type":"article","og_title":"Cate Lockhart &#8226; BioTech Pharma Summit","og_description":"Joa\u0303o Gonc\u0327alves is Head of the Biopharmaceutical Biotechnology Unit at the Institute of Innovative Medicines and Instituto de Medicina Molecular","og_url":"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/cate-lockhart\/","og_site_name":"BioTech Pharma Summit","article_publisher":"https:\/\/www.facebook.com\/biotechpharmasummit\/","article_modified_time":"2021-03-18T11:24:11+00:00","og_image":[{"width":900,"height":900,"url":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Lockhart_Cate_Biologics_Biosimilars_Collective_Intelligence_Consortium_BBCIC_BioTech_Pharma_Summit.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_site":"@biotechsummit","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/cate-lockhart\/","url":"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/cate-lockhart\/","name":"Cate Lockhart &#8226; BioTech Pharma Summit","isPartOf":{"@id":"https:\/\/www.biotechpharmasummit.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/cate-lockhart\/#primaryimage"},"image":{"@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/cate-lockhart\/#primaryimage"},"thumbnailUrl":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Lockhart_Cate_Biologics_Biosimilars_Collective_Intelligence_Consortium_BBCIC_BioTech_Pharma_Summit.jpg","datePublished":"2020-08-13T13:31:57+00:00","dateModified":"2021-03-18T11:24:11+00:00","description":"Joa\u0303o Gonc\u0327alves is Head of the Biopharmaceutical Biotechnology Unit at the Institute of Innovative Medicines and Instituto de Medicina Molecular","breadcrumb":{"@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/cate-lockhart\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/cate-lockhart\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/cate-lockhart\/#primaryimage","url":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Lockhart_Cate_Biologics_Biosimilars_Collective_Intelligence_Consortium_BBCIC_BioTech_Pharma_Summit.jpg","contentUrl":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Lockhart_Cate_Biologics_Biosimilars_Collective_Intelligence_Consortium_BBCIC_BioTech_Pharma_Summit.jpg","width":900,"height":900},{"@type":"BreadcrumbList","@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/cate-lockhart\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.biotechpharmasummit.com\/"},{"@type":"ListItem","position":2,"name":"Biosimilars &#038; Biologics 2019 Speakers","item":"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/"},{"@type":"ListItem","position":3,"name":"Cate Lockhart"}]},{"@type":"WebSite","@id":"https:\/\/www.biotechpharmasummit.com\/#website","url":"https:\/\/www.biotechpharmasummit.com\/","name":"BioTech Pharma Summit","description":"The Tomorrow&#039;s healthcare congress","publisher":{"@id":"https:\/\/www.biotechpharmasummit.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.biotechpharmasummit.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.biotechpharmasummit.com\/#organization","name":"EPM Group","url":"https:\/\/www.biotechpharmasummit.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png","contentUrl":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png","width":2000,"height":2000,"caption":"EPM Group"},"image":{"@id":"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/biotechpharmasummit\/","https:\/\/x.com\/biotechsummit","https:\/\/www.instagram.com\/biotechpharmasummit\/","https:\/\/www.linkedin.com\/company\/biotech-pharma-summit\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages\/33500","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/comments?post=33500"}],"version-history":[{"count":4,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages\/33500\/revisions"}],"predecessor-version":[{"id":36002,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages\/33500\/revisions\/36002"}],"up":[{"embeddable":true,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages\/33455"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/media\/33501"}],"wp:attachment":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/media?parent=33500"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}